A drug that was previously feared to cause deformities in unborn children is now the preferred HIV treatment option. The World Health Organisation (WHO) says women of reproductive age are included in the population. The organisation says it is updating its HIV therapy guidelines to strengthen its recommendation for dolutegravir (DTG) drug as the first-line treatment because of its efficacy, tolerability and a high genetic barrier to resistance.
This decision, according to the WHO, was arrived at after considering mathematical models of the benefits and harm associated with two HIV drugs (dolutegravir and Efavirenz), the values and preferences of people with HIV as well as factors related to the implementation of HIV programmes in different countries and cost. Iran open to UK tanker swap amid hopes for 'progress' There had been fears about the risk of defects in the brain, spine or…
